ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

148
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals Co.,Ltd develops, manufactures, and markets medicines and medicine packing materials. The Company produces anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foils, and other related products. Jiangsu Hengrui Pharmaceuticals conducts business in China, America, Japan, Korea, Europe, and Australia.
more
•29 Apr 2025 11:41

Hainan Drinda New Energy (A/H IPO) - Business Was Acquired for 1/3rd the Price, Three Years Ago

Hainan Drinda Automotive Trim (002865 CH) plans to raise up to US$234m via its A/H listing. In this note, we look at the past performance and talk...

Logo
470 Views
Share
bearish•Horizon Robotics
•16 Apr 2025 09:48

Horizon Robotics IPO Lockup- US$7bn Expiry with Scattered Shareholding and Lots of CCASS Movement

Horizon Robotics (9660 HK) raised around US$800m in its Hong Kong IPO in October 2024. The lockup on its pre-IPO investors is set to expire soon.

Logo
918 Views
Share
bullish•WuXi XDC Cayman
•01 Apr 2025 19:11

Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed

WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...

Logo
454 Views
Share
•27 Mar 2025 10:10

A/H Premiums and past A/H Listings Performance Data - Mixed Results but Size Matters

Given the slew of A/H offerings in the Hong Kong IPO pipeline, in this note, we talk about the overall A/H premiums currently.

Logo
555 Views
Share
bearish•HLB Life Science
•25 Mar 2025 22:47

HLB Life Science (067630 KS): FDA Rejects Oncology Drug AGAIN; What Lies Ahead

​HLB Life Science shares dropped 20% as group company Elevar Therapeutics faces setback with FDA rejecting new cancer drug application for...

Logo
434 Views
Share
x